Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C23H36O7 |
Molecular Weight | 424.5286 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@]([H])(C)C(=O)O[C@@]1([H])C[C@@]([H])(C=C2C=C[C@]([H])(C)[C@]([H])(CC[C@]([H])(C[C@]([H])(CC(=O)O)O)O)[C@]21[H])O
InChI
InChIKey=TUZYXOIXSAXUGO-PZAWKZKUSA-N
InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1
DescriptionCurator's Comment:: description was created based on several sources, including
https://www.drugs.com/pravastatin.html | https://www.ncbi.nlm.nih.gov/pubmed/16960448 | http://reference.medscape.com/drug/pravachol-pravastatin-342460 | https://www.drugbank.ca/drugs/DB00175
Curator's Comment:: description was created based on several sources, including
https://www.drugs.com/pravastatin.html | https://www.ncbi.nlm.nih.gov/pubmed/16960448 | http://reference.medscape.com/drug/pravachol-pravastatin-342460 | https://www.drugbank.ca/drugs/DB00175
Pravastatin (marketed as Pravachol or Selektine) is a member of the drug class of statins, used in combination with diet, exercise, and weight loss for lowering cholesterol and preventing cardiovascular disease. Pravastatin acts as a lipoprotein-lowering drug through two pathways. In the major pathway, pravastatin inhibits the function of hydroxymethylglutaryl-CoA (HMG-CoA) reductase. As a reversible competitive inhibitor, pravastatin sterically hinders the action of HMG-CoA reductase by occupying the active site of the enzyme. Taking place primarily in the liver, this enzyme is responsible for the conversion of HMG-CoA to mevalonate in the rate-limiting step of the biosynthetic pathway for cholesterol. Pravastatin also inhibits the synthesis of very-low-density lipoproteins, which are the precursor to low-density lipoproteins (LDL). These reductions increase the number of cellular LDL receptors, thus LDL uptake increases, removing it from the bloodstream. Pravastatin is primarily used for the treatment of dyslipidemia and the prevention of cardiovascular disease. It is recommended to be used only after other measures, such as diet, exercise, and weight reduction, have not improved cholesterol levels. The evidence for the use of pravastatin is generally weaker than for other statins. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT), failed to demonstrate a difference in all-cause mortality or nonfatal myocardial infarction/fatal coronary heart disease rates between patients receiving pravastatin 40 mg daily (a common starting dose) and those receiving usual care. Pravastatin is generally well tolerated; adverse reactions have usually been mild and transient. In 4-month-long placebo-controlled trials, 1.7% of Pravastatin-treated patients and 1.2% of placebo-treated patients were discontinued from treatment because of adverse experiences attributed to study drug therapy; this difference was not statistically significant.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL402 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11392538 |
1370.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PRAVACHOL Approved UseTherapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. Pravastatin sodium tablet, USP is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of MI, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident CHD. ( 1.1) Reduce the risk of total mortality by reducing coronary death, MI, revascularization, stroke/TIA, and the progression of coronary atherosclerosis in patients with clinically evident CHD. ( 1.1) Reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia. ( 1.2) Reduce elevated serum TG levels in patients with hypertriglyceridemia. ( 1.2) Treat patients with primary dysbetalipoproteinemia who are not responding to diet. ( 1.2) Treat children and adolescent patients ages 8 years and older with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. ( 1.2) Limitations of use: Pravastatin sodium tablets, USP have not been studied in Fredrickson Types I and V dyslipidemias. ( 1.3) 1.1 Prevention of Cardiovascular Disease In hypercholesterolemic patients without clinically evident coronary heart disease (CHD), pravastatin sodium tablets, USP are indicated to: reduce the risk of myocardial infarction (MI). reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. In patients with clinically evident CHD, pravastatin sodium tablet is indicated to: reduce the risk of total mortality by reducing coronary death. reduce the risk of MI. reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of stroke and stroke/transient ischemic attack (TIA). slow the progression of coronary atherosclerosis. 1.2 Hyperlipidemia Pravastatin sodium tablet is indicated: as an adjunct to diet to reduce elevated total cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and triglyceride (TG) levels and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia ( Fredrickson Types IIa and IIb). 1 as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV). for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet. as an adjunct to diet and lifestyle modification for treatment of heterozygous familial hypercholesterolemia (HeFH) in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors are present in the patient. 1.3 Limitations of Use Pravastatin sodium has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). Launch Date6.8886718E11 |
|||
Primary | PRAVACHOL Approved UseTherapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. Pravastatin sodium tablet, USP is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of MI, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident CHD. ( 1.1) Reduce the risk of total mortality by reducing coronary death, MI, revascularization, stroke/TIA, and the progression of coronary atherosclerosis in patients with clinically evident CHD. ( 1.1) Reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia. ( 1.2) Reduce elevated serum TG levels in patients with hypertriglyceridemia. ( 1.2) Treat patients with primary dysbetalipoproteinemia who are not responding to diet. ( 1.2) Treat children and adolescent patients ages 8 years and older with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. ( 1.2) Limitations of use: Pravastatin sodium tablets, USP have not been studied in Fredrickson Types I and V dyslipidemias. ( 1.3) 1.1 Prevention of Cardiovascular Disease In hypercholesterolemic patients without clinically evident coronary heart disease (CHD), pravastatin sodium tablets, USP are indicated to: reduce the risk of myocardial infarction (MI). reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. In patients with clinically evident CHD, pravastatin sodium tablet is indicated to: reduce the risk of total mortality by reducing coronary death. reduce the risk of MI. reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of stroke and stroke/transient ischemic attack (TIA). slow the progression of coronary atherosclerosis. 1.2 Hyperlipidemia Pravastatin sodium tablet is indicated: as an adjunct to diet to reduce elevated total cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and triglyceride (TG) levels and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia ( Fredrickson Types IIa and IIb). 1 as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV). for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet. as an adjunct to diet and lifestyle modification for treatment of heterozygous familial hypercholesterolemia (HeFH) in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors are present in the patient. 1.3 Limitations of Use Pravastatin sodium has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). Launch Date6.8886718E11 |
|||
Primary | PRAVACHOL Approved UseTherapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. Pravastatin sodium tablet, USP is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of MI, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident CHD. ( 1.1) Reduce the risk of total mortality by reducing coronary death, MI, revascularization, stroke/TIA, and the progression of coronary atherosclerosis in patients with clinically evident CHD. ( 1.1) Reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia. ( 1.2) Reduce elevated serum TG levels in patients with hypertriglyceridemia. ( 1.2) Treat patients with primary dysbetalipoproteinemia who are not responding to diet. ( 1.2) Treat children and adolescent patients ages 8 years and older with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. ( 1.2) Limitations of use: Pravastatin sodium tablets, USP have not been studied in Fredrickson Types I and V dyslipidemias. ( 1.3) 1.1 Prevention of Cardiovascular Disease In hypercholesterolemic patients without clinically evident coronary heart disease (CHD), pravastatin sodium tablets, USP are indicated to: reduce the risk of myocardial infarction (MI). reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. In patients with clinically evident CHD, pravastatin sodium tablet is indicated to: reduce the risk of total mortality by reducing coronary death. reduce the risk of MI. reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of stroke and stroke/transient ischemic attack (TIA). slow the progression of coronary atherosclerosis. 1.2 Hyperlipidemia Pravastatin sodium tablet is indicated: as an adjunct to diet to reduce elevated total cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and triglyceride (TG) levels and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia ( Fredrickson Types IIa and IIb). 1 as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV). for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet. as an adjunct to diet and lifestyle modification for treatment of heterozygous familial hypercholesterolemia (HeFH) in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors are present in the patient. 1.3 Limitations of Use Pravastatin sodium has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). Launch Date6.8886718E11 |
|||
Primary | PRAVACHOL Approved UseTherapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. Pravastatin sodium tablet, USP is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of MI, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident CHD. ( 1.1) Reduce the risk of total mortality by reducing coronary death, MI, revascularization, stroke/TIA, and the progression of coronary atherosclerosis in patients with clinically evident CHD. ( 1.1) Reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia. ( 1.2) Reduce elevated serum TG levels in patients with hypertriglyceridemia. ( 1.2) Treat patients with primary dysbetalipoproteinemia who are not responding to diet. ( 1.2) Treat children and adolescent patients ages 8 years and older with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. ( 1.2) Limitations of use: Pravastatin sodium tablets, USP have not been studied in Fredrickson Types I and V dyslipidemias. ( 1.3) 1.1 Prevention of Cardiovascular Disease In hypercholesterolemic patients without clinically evident coronary heart disease (CHD), pravastatin sodium tablets, USP are indicated to: reduce the risk of myocardial infarction (MI). reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. In patients with clinically evident CHD, pravastatin sodium tablet is indicated to: reduce the risk of total mortality by reducing coronary death. reduce the risk of MI. reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of stroke and stroke/transient ischemic attack (TIA). slow the progression of coronary atherosclerosis. 1.2 Hyperlipidemia Pravastatin sodium tablet is indicated: as an adjunct to diet to reduce elevated total cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and triglyceride (TG) levels and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia ( Fredrickson Types IIa and IIb). 1 as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV). for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet. as an adjunct to diet and lifestyle modification for treatment of heterozygous familial hypercholesterolemia (HeFH) in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors are present in the patient. 1.3 Limitations of Use Pravastatin sodium has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). Launch Date6.8886718E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
27.4 μg/L |
19.2 mg single, oral dose: 19.2 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRAVASTATIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
66.2 μg × h/mL |
19.2 mg single, oral dose: 19.2 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRAVASTATIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
241.29 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00829309 |
80 mg single, oral dose: 80 mg route of administration: oral experiment type: single co-administered: |
PRAVASTATIN plasma | Homo sapiens population: healthy age: sex: food status: Fed |
|
251.86 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00829309 |
80 mg single, oral dose: 80 mg route of administration: oral experiment type: single co-administered: |
PRAVASTATIN plasma | Homo sapiens population: healthy age: sex: food status: Fed |
|
273.32 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00829309 |
80 mg single, oral dose: 80 mg route of administration: oral experiment type: single co-administered: |
PRAVASTATIN plasma | Homo sapiens population: healthy age: sex: food status: Fed |
|
299.56 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00829309 |
80 mg single, oral dose: 80 mg route of administration: oral experiment type: single co-administered: |
PRAVASTATIN plasma | Homo sapiens population: healthy age: sex: food status: Fed |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.77 h |
19.2 mg single, oral dose: 19.2 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRAVASTATIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
weak [IC50 352 uM] | ||||
weak [IC50 408 uM] | ||||
weak [IC50 591 uM] | ||||
yes [IC50 13.7 uM] | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | no (co-administration study) Comment: see https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019898s060lbl.pdf#page=19 |
|||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | yes (co-administration study) Comment: Coadministration with cyclosporine (inhibitor): AUC increased 5-10 fold |
PubMed
Title | Date | PubMed |
---|---|---|
Advantages of lipid-lowering therapy in cerebral ischemia: role of HMG-CoA reductase inhibitors. | 2001 |
|
Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. | 2001 Apr |
|
Recent clinical trial highlights in hypertension. | 2001 Apr |
|
Cell cycle-related changes in regulatory volume decrease and volume-sensitive chloride conductance in mouse fibroblasts. | 2001 Apr |
|
[Acute coronary syndrome. Early lipid reduction decreases risk of recurrence]. | 2001 Apr 19 |
|
Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. | 2001 Apr 6 |
|
[Statins: intervention studies, facts and perspectives]. | 2001 Feb |
|
Protective effect of fluvastatin on degradation of apolipoprotein B by a radical reaction in human plasma. | 2001 Feb |
|
Do HMG-CoA reductase inhibitors affect fibrinogen? | 2001 Feb |
|
Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). | 2001 Feb |
|
Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. | 2001 Feb 20 |
|
[Acute coronary syndrome. Statins in the early phase save lives]. | 2001 Feb 8 |
|
Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. | 2001 Jan |
|
Cholesterol-dependent modulation of tau phosphorylation in cultured neurons. | 2001 Jan |
|
Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima-media thickness in the moderately hypercholesterolaemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian Study. PHYLLIS study group. | 2001 Jan |
|
Statin trials in progress: unanswered questions. | 2001 Jan |
|
Effective use of statins to prevent coronary heart disease. | 2001 Jan 15 |
|
Use of the statins in patients after acute myocardial infarction: does evidence change practice? | 2001 Jan 22 |
|
Interim monitoring of clinical trials based on long-term binary endpoints. | 2001 Jan 30 |
|
Beneficial effects of pravastatin in peri- and postmenopausal hyperlipidemic women: a 5-year study on serum lipid and sex hormone levels. | 2001 Jan 31 |
|
Inflammation and coronary heart disease: an overview. | 2001 Jan-Feb |
|
Statin therapy and the prevention of dementia. | 2001 Jun |
|
Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients. | 2001 Jun |
|
Simvastatin-associated memory loss. | 2001 Jun |
|
HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress. | 2001 Jun |
|
Randomized clinical trials and recent patterns in the use of statins. | 2001 Jun |
|
Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. | 2001 Jun |
|
Limitation of heart growth in neonatal piglets by simvastatin and atorvastatin: comparison with pravastatin. | 2001 Jun |
|
Compactin enhances osteogenesis in murine embryonic stem cells. | 2001 Jun 8 |
|
Is a statin a statin? | 2001 Mar |
|
Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population. | 2001 Mar |
|
Statin therapy--what now? | 2001 Mar |
|
Design and rationale of the ARBITER trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)--a randomized trial comparing the effects of atorvastatin and pravastatin on carotid artery intima-media thickness. | 2001 Mar |
|
A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. | 2001 Mar |
|
Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients. | 2001 Mar 15 |
|
What do the statin trials tell us? | 2001 May |
|
Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. | 2001 May |
|
Cholesterol ester accumulation: an immediate consequence of acute in vivo ischemic renal injury. | 2001 May |
|
[Statins as new therapeutic possibility in osteoporosis?]. | 2001 May 11 |
|
Summaries for patients. Benefits of lowering cholesterol levels in older patients. | 2001 May 15 |
|
Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. | 2001 May 15 |
|
Cost effectiveness of HMG-CoA reductase inhibition in Canada. | 2001 Spring |
Sample Use Guides
May be beneficial for prophylaxis of cardiovascular events in at-risk patients, even if patients have normal levels of cholesterol.
10-40 mg PO qDay; not to exceed 80 mg/day
Initiate with 10 mg qHS if taking immunosuppressants like cyclosporine concurrently; not to exceed 20 mg/day
Limit maximum to 40 mg/day if taking concurrently with clarithromycin
Dose adjustments should be made at intervals of 4 weeks or more; individualize dosing according to baseline LDL cholesterol levels
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11392538
Pravastatin activity was evaluated using cellular steroidgenesis assay in Hep G2cells (human hepatoma cell line) cultured with 5% lipoprotein deficient serum containing medium for 48 h. The activities were determined by decreased incorporation of sodium [2-14C] acetate into non-saponifiable lipids.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC10BX02
Created by
admin on Sat Jun 26 02:51:26 UTC 2021 , Edited by admin on Sat Jun 26 02:51:26 UTC 2021
|
||
|
NDF-RT |
N0000175589
Created by
admin on Sat Jun 26 02:51:26 UTC 2021 , Edited by admin on Sat Jun 26 02:51:26 UTC 2021
|
||
|
WHO-VATC |
QC10BA03
Created by
admin on Sat Jun 26 02:51:26 UTC 2021 , Edited by admin on Sat Jun 26 02:51:26 UTC 2021
|
||
|
WHO-VATC |
QC10AA03
Created by
admin on Sat Jun 26 02:51:26 UTC 2021 , Edited by admin on Sat Jun 26 02:51:26 UTC 2021
|
||
|
WHO-ATC |
C10BA03
Created by
admin on Sat Jun 26 02:51:25 UTC 2021 , Edited by admin on Sat Jun 26 02:51:25 UTC 2021
|
||
|
LIVERTOX |
791
Created by
admin on Sat Jun 26 02:51:26 UTC 2021 , Edited by admin on Sat Jun 26 02:51:26 UTC 2021
|
||
|
WHO-ATC |
C10BX02
Created by
admin on Sat Jun 26 02:51:25 UTC 2021 , Edited by admin on Sat Jun 26 02:51:25 UTC 2021
|
||
|
WHO-ATC |
C10AA03
Created by
admin on Sat Jun 26 02:51:25 UTC 2021 , Edited by admin on Sat Jun 26 02:51:25 UTC 2021
|
||
|
NDF-RT |
N0000000121
Created by
admin on Sat Jun 26 02:51:26 UTC 2021 , Edited by admin on Sat Jun 26 02:51:26 UTC 2021
|
||
|
NCI_THESAURUS |
C1655
Created by
admin on Sat Jun 26 02:51:26 UTC 2021 , Edited by admin on Sat Jun 26 02:51:26 UTC 2021
|
||
|
EU-Orphan Drug |
EU/3/10/748
Created by
admin on Sat Jun 26 02:51:26 UTC 2021 , Edited by admin on Sat Jun 26 02:51:26 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2239
Created by
admin on Sat Jun 26 02:51:26 UTC 2021 , Edited by admin on Sat Jun 26 02:51:26 UTC 2021
|
PRIMARY | |||
|
54687
Created by
admin on Sat Jun 26 02:51:26 UTC 2021 , Edited by admin on Sat Jun 26 02:51:26 UTC 2021
|
PRIMARY | |||
|
KXO2KT9N0G
Created by
admin on Sat Jun 26 02:51:26 UTC 2021 , Edited by admin on Sat Jun 26 02:51:26 UTC 2021
|
PRIMARY | |||
|
81093-37-0
Created by
admin on Sat Jun 26 02:51:25 UTC 2021 , Edited by admin on Sat Jun 26 02:51:25 UTC 2021
|
PRIMARY | |||
|
2953
Created by
admin on Sat Jun 26 02:51:26 UTC 2021 , Edited by admin on Sat Jun 26 02:51:26 UTC 2021
|
PRIMARY | |||
|
DB00175
Created by
admin on Sat Jun 26 02:51:26 UTC 2021 , Edited by admin on Sat Jun 26 02:51:26 UTC 2021
|
PRIMARY | |||
|
PRAVASTATIN
Created by
admin on Sat Jun 26 02:51:26 UTC 2021 , Edited by admin on Sat Jun 26 02:51:26 UTC 2021
|
PRIMARY | |||
|
D017035
Created by
admin on Sat Jun 26 02:51:26 UTC 2021 , Edited by admin on Sat Jun 26 02:51:26 UTC 2021
|
PRIMARY | |||
|
SUB10004MIG
Created by
admin on Sat Jun 26 02:51:26 UTC 2021 , Edited by admin on Sat Jun 26 02:51:26 UTC 2021
|
PRIMARY | |||
|
81093-37-0
Created by
admin on Sat Jun 26 02:51:26 UTC 2021 , Edited by admin on Sat Jun 26 02:51:26 UTC 2021
|
PRIMARY | |||
|
6070
Created by
admin on Sat Jun 26 02:51:26 UTC 2021 , Edited by admin on Sat Jun 26 02:51:26 UTC 2021
|
PRIMARY | |||
|
CHEMBL1144
Created by
admin on Sat Jun 26 02:51:26 UTC 2021 , Edited by admin on Sat Jun 26 02:51:26 UTC 2021
|
PRIMARY | |||
|
Pravastatin
Created by
admin on Sat Jun 26 02:51:26 UTC 2021 , Edited by admin on Sat Jun 26 02:51:26 UTC 2021
|
PRIMARY | |||
|
42463
Created by
admin on Sat Jun 26 02:51:26 UTC 2021 , Edited by admin on Sat Jun 26 02:51:26 UTC 2021
|
PRIMARY | RxNorm | ||
|
C62070
Created by
admin on Sat Jun 26 02:51:26 UTC 2021 , Edited by admin on Sat Jun 26 02:51:26 UTC 2021
|
PRIMARY | |||
|
8368
Created by
admin on Sat Jun 26 02:51:26 UTC 2021 , Edited by admin on Sat Jun 26 02:51:26 UTC 2021
|
PRIMARY |
ACTIVE MOIETY
METABOLITE INACTIVE (PARENT)
METABOLITE INACTIVE (PARENT)
METABOLITE LESS ACTIVE (PARENT)
METABOLITE LESS ACTIVE (PARENT)
PARENT (METABOLITE INACTIVE)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)